How many drugs treat Major Nerve Block for Surgery?

Drug Landscape tracks 8 marketed treatments for Major Nerve Block for Surgery (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/major-nerve-block-for-surgery.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Major Nerve Block for Surgery — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Major Nerve Block for Surgery (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Major Nerve Block for Surgery, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Chirocain	LEVOBUPIVACAINE	Purdue Pharma Lp	levobupivacaine	Cytochrome P450 2D6	1999-01-01
Naropin	ROPIVACAINE	Fresenius Kabi	Amide Local Anesthetic	Sodium channel protein type 5 subunit alpha	1996-01-01
Bupivacaine Hydrochloride	Bupivacaine Hydrochloride	Pfizer	Amide-type local anesthetic	Nerve sodium channels	1972-01-01
Bupivacaine Hydrochloride And Epinephrine	BUPIVACAINE	Innocoll	Amide Local Anesthetic	Cytochrome P450 2D6	1972-01-01
Ropivacain	Ropivacain	University Hospital, Basel, Switzerland		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Bupivacain	Bupivacain	Sisli Hamidiye Etfal Training and Research Hospital		5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3
Naropeine	Naropeine	University Hospital, Rouen		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha
Naropine	Naropine	Rigshospitalet, Denmark		Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Fresenius Kabi · 1 drug in Major Nerve Block for Surgery
Innocoll · 1 drug in Major Nerve Block for Surgery
Pfizer · 1 drug in Major Nerve Block for Surgery
Purdue Pharma Lp · 1 drug in Major Nerve Block for Surgery
Rigshospitalet, Denmark · 1 drug in Major Nerve Block for Surgery
Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in Major Nerve Block for Surgery
University Hospital, Basel, Switzerland · 1 drug in Major Nerve Block for Surgery
University Hospital, Rouen · 1 drug in Major Nerve Block for Surgery

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Major Nerve Block for Surgery:

Cite this brief

Drug Landscape (2026). Major Nerve Block for Surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/major-nerve-block-for-surgery. Accessed 2026-06-10.

Major Nerve Block for Surgery full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing